Hematology specialist medical group Lu Daopei Medical Group has completed more than 100 million yuan in B+ round of equity financing. This round of financing was led by Yueyin Medical Fund, followed by China Merchants Securities Capital, SoftBank China Capital, Zhonghe Capital and old shareholder Park Road Capital. cast.

Lu Daopei Medical Group was founded in 2001 by Academician Lu Daopei, a Chinese hematology expert. After nearly 20 years of development, it now has four for-profit three hospitals: Hebei Lu Daopei Hematology Hospital, Beijing Lu Daopei Hospital, Beijing Lu Daopei Hematology Hospital and Shanghai Daopei Hospital. The group hospital has an area of more than 100,000 square meters, more than 1,200 beds, and 108 hematopoietic stem cell transplant warehouses.

In addition, Lu Daopei Medical Group has become one of the most active hematopoietic stem cell transplantation centers in the world. It is reported that in 2019, Lu Daopei Hospital successfully completed 1,081 hematopoietic stem cell transplants, making it the largest transplant center in China, 70% of which were haploidentical transplants, which greatly improved the chances of hematological tumor patients finding a donor, thus enabling most patients to be transplanted.

It is understood that in 2015, Lu Daopei Hospital began to engage in clinical trial research of CART in the treatment of leukemia, and was one of the earliest centers in the country to carry out this research. As of the end of June 2020, Lu Daopei Hospital has completed 914 CART clinical trials, and has formed a CART bridge transplantation technology with Lu Daopei's characteristics.